肺叶切除、肺段切除或楔形切除治疗外周临床T1aN0非小细胞肺癌:CALGB 140503(Alliance)的事后分析
CALGB 140503随机试验事后分析比较外周cT1aN0非小细胞肺癌行肺叶切除、肺段切除或楔形切除的生存差异。697例随机分组,5年无病生存、总生存及肺癌特异性生存三组间均无显著差异;楔形切除局部区域复发率数值上高于肺段切除但无统计学意义;术后6个月FEV1下降百分比两组无显著差异。
要点
- 肺叶、肺段、楔形切除三组5年无病生存、总生存、肺癌特异性生存均无显著差异。
- 楔形切除局部区域复发率12% vs 肺段切除14%,差异无统计学意义。
- 术后6个月FEV1下降百分比楔形切除5% vs 肺段切除3%,无显著差异。
核心结论
- 在这项大型随机试验中,肺叶切除、肺段切除和楔形切除与相似的生存结局相关。
- 楔形切除后局部区域复发率数值上高于肺段切除,但差异无统计学意义。
- 肺段切除组与楔形切除组之间FEV1下降无显著差异。
研究设计与样本
- CALGB 140503(Alliance)随机试验的事后分析,2007年6月至2017年3月共随机697例外周cT1aN0非小细胞肺癌患者。
- 按临床肿瘤大小、组织学和吸烟史分层随机至肺叶切除(n=357)或亚肺叶切除(n=340)。
- 10例由亚肺叶切除转为肺叶切除,5例由肺叶切除转为亚肺叶切除;实际分析肺叶切除362例、肺段切除131例、楔形切除204例。
主要发现
- 5年无病生存:肺叶切除64.7%(95%CI 59.6%-70.1%),肺段切除63.8%(95%CI 55.6%-73.2%),楔形切除62.5%(95%CI 55.8%-69.9%)(P=.888,log-rank检验)。
- 5年总生存:肺叶切除78.7%,肺段切除81.9%,楔形切除79.7%(P=.873,log-rank检验)。
- 5年肺癌特异性生存:肺叶切除86.8%,肺段切除89.2%,楔形切除89.7%(P=.903,log-rank检验)。
- 局部区域复发:肺段切除12%,楔形切除14%(P=.295)。
- 术后6个月FEV1下降百分比中位数:楔形切除5%,肺段切除3%(P=.930)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have recently reported the primary results of CALGB 140503 (Alliance), a randomized trial in patients with peripheral cT1aN0 non-small cell lung cancer (American Joint Committee on Cancer seventh) treated with either lobar resection (LR) or sublobar resection (SLR). Here we report differences in disease-free survival (DFS), overall survival (OS) and lung cancer-specific survival (LCSS) between LR, segmental resection (SR), and wedge resection (WR). We also report differences between WR and SR in terms of surgical margins, rate of locoregional recurrence (LRR), and expiratory flow rate at 6 months postoperatively. METHODS: Between June 2007 and March 2017, a total of 697 patients were randomized to LR (n = 357) or SLR (n = 340) stratified by clinical tumor size, histology, and smoking history. Ten patients were converted from SLR to LR, and 5 patients were converted from LR to SLR. Survival endpoints were estimated using the Kaplan-Maier estimator and tested by the stratified log-rank test. The Kruskal-Wallis test was used to compare margins and changes in forced expiratory volume in 1 second (FEV1) between groups, and the χ2 test was used to test the associations between recurrence and groups. RESULTS: A total of 362 patients had LR, 131 had SR, and 204 had WR. Basic demographic and clinical and pathologic characteristics were similar in the 3 groups. Five-year DFS was 64.7% after LR (95% confidence interval [CI], 59.6%-70.1%), 63.8% after SR (95% CI, 55.6%-73.2%), and 62.5% after WR (95% CI, 55.8%-69.9%) (P = .888, log-rank test). Five-year OS was 78.7% after LR, 81.9% after SR, and 79.7% after WR (P = .873, log-rank test). Five-year LCSS was 86.8% after LR, 89.2% after SR, and 89.7% after WR (P = .903, log-rank test). LRR occurred in 12% after SR and in 14% after WR (P = .295). At 6 months postoperatively, the median reduction in % FEV1 was 5% after WR and 3% after SR (P = .930). CONCLUSIONS: In this large randomized trial, LR, SR, and WR were associated with similar survival outcomes. Although LRR was numerically higher after WR compared to SR, the difference was not statistically significant. There was no significant difference in the reduction of FEV1 between the SR and WR groups.
引用
- Altorki N, Wang X, Damman B, et al. Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance). J Thorac Cardiovasc Surg. 2023. PMID: 37473998. doi:10.1016/j.jtcvs.2023.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。